Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Opyl Ltd. ( (AU:PKY) ) is now available.
Pathkey.AI has appointed defence and AI systems specialist Andrew Farnsworth as chief executive officer, formalising a role he has effectively played during a six-month strategic review that reframed the company as an applied AI platform provider beyond healthcare. Farnsworth, whose background spans the Royal Australian Air Force, secure communications, cyber infrastructure and senior technology roles at Yum! Brands, Sephora Asia and Marina Bay Sands, brings deep experience in large-scale AI transformation, cybersecurity and commercialisation of technology products.
His appointment is closely tied to Pathkey’s planned acquisition of Singapore-based Chipforge, whose AI-driven chip design platform aims to cut the time and cost of custom semiconductor development. The board views Farnsworth’s blend of defence-grade security expertise and enterprise product leadership as critical to scaling TrialKey and Chipforge across data-intensive, regulated industries, signalling a push to broaden Pathkey’s market reach and strengthen its position in AI-enabled infrastructure and clinical research solutions.
More about Opyl Ltd.
Pathkey.AI Ltd, listed on the ASX as PKY, is an AI-powered platform technology company focused on developing and commercialising artificial intelligence solutions for data-sensitive and regulated industries. Its key products include the TrialKey clinical trials platform for clinical research and the Chipforge AI-powered chip design platform aimed at semiconductor engineering, serving sectors such as healthcare, defence, critical infrastructure and other regulated markets.
Average Trading Volume: 3,581,621
Technical Sentiment Signal: Buy
Current Market Cap: A$32.18M
See more insights into PKY stock on TipRanks’ Stock Analysis page.